✦ LIBER ✦

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

✍ Scribed by Tokuda, Y; Watanabe, T; Omuro, Y; Ando, M; Katsumata, N; Okumura, A; Ohta, M; Fujii, H; Sasaki, Y; Niwa, T

Book ID: 110002161
Publisher: Nature Publishing Group
Year: 1999
Tongue: English
Weight: 331 KB
Volume: 81
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6690343

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of a HER2/neu bispecific

A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu

✍ V. Pullarkat; Y. Deo; J. Link; L. Spears; V. Marty; R. Curnow; S. Groshen; C. Ge 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 365 KB

A virosomal formulated Her-2/neu multi-p

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

✍ Ursula Wiedermann; C. Wiltschke; J. Jasinska; M. Kundi; R. Zurbriggen; E. Garner 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 321 KB

Targeting endothelin A receptor enhances

Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells

✍ Jeanett Fischgräbe; Martin Götte; Katharina Michels; Ludwig Kiesel; Pia Wülfing 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 600 KB

Human epidermal growth factor receptor 2 (HER2) is frequently overexpressed in human breast cancers. It is known to drive tumor growth and progression and represents a prominent target in breast cancer therapy. The endothelin (ET) system, in particular ET-1 and its receptor ET A R, is of major relev

Paraneoplastic Cerebellar Degeneration w

Paraneoplastic Cerebellar Degeneration with Anti-Yo Antibody in a Patient with HER2/neu Overexpressing Breast Cancer: A Case Report with a Current Literature Review

✍ Shin Ogita; Omar H. Llaguna; Sheldon M. Feldman; Ronald Blum 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

A phase II study of trastuzumab and cape

A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial

✍ Daigo Yamamoto; Satoru Iwase; Kaoru Kitamura; Hiroki Odagiri; Chizuko Yamamoto; 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 232 KB

HER2 overexpression as a prognostic fact

HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support

✍ Guarneri, V; Bengala, C; Orlandini, C; Gennari, A; Donati, S; Campani, D; Collec 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 124 KB